Filter search criteria using below inputs
Click on magnifying glass icon to search
Company | Country | Symbol |
---|
Time | Volume | MDGL |
---|---|---|
09:32 ET | 2888 | 275.5 |
09:34 ET | 850 | 275.91 |
09:36 ET | 462 | 276.115 |
09:38 ET | 1658 | 278.09 |
09:39 ET | 900 | 280 |
09:41 ET | 1877 | 276.94 |
09:43 ET | 708 | 277.995 |
09:45 ET | 200 | 278.1 |
09:50 ET | 660 | 279.85 |
09:52 ET | 300 | 280 |
09:54 ET | 379 | 280.27 |
09:56 ET | 1165 | 282.5 |
09:57 ET | 179 | 281.24 |
09:59 ET | 300 | 282.5 |
10:06 ET | 100 | 282.06 |
10:08 ET | 265 | 280.24 |
10:12 ET | 600 | 282.035 |
10:14 ET | 100 | 281.385 |
10:21 ET | 276 | 281.225 |
10:26 ET | 200 | 280.86 |
10:28 ET | 100 | 281.9 |
10:32 ET | 275 | 281.305 |
10:33 ET | 200 | 280.15 |
10:37 ET | 200 | 280.44 |
10:39 ET | 1100 | 280.455 |
10:42 ET | 450 | 281.05 |
10:44 ET | 100 | 281.78 |
10:46 ET | 700 | 281.42 |
10:50 ET | 100 | 280.65 |
10:53 ET | 200 | 280.655 |
10:55 ET | 303 | 280.645 |
10:57 ET | 200 | 281.35 |
11:04 ET | 100 | 282 |
11:13 ET | 1000 | 279.105 |
11:15 ET | 200 | 278.4784 |
11:18 ET | 1036 | 277.945 |
11:20 ET | 1300 | 278.6 |
11:22 ET | 200 | 278.96 |
11:26 ET | 200 | 279.69 |
11:27 ET | 300 | 280.03 |
11:31 ET | 100 | 279.84 |
11:33 ET | 500 | 279.45 |
11:36 ET | 800 | 279.385 |
11:40 ET | 100 | 279.365 |
11:42 ET | 100 | 279.32 |
11:44 ET | 400 | 279.11 |
11:47 ET | 400 | 279.06 |
11:49 ET | 200 | 278.98 |
12:00 ET | 200 | 278.36 |
12:03 ET | 100 | 277.515 |
12:05 ET | 200 | 277.43 |
12:09 ET | 400 | 277.235 |
12:12 ET | 100 | 277.195 |
12:14 ET | 299 | 276.975 |
12:16 ET | 100 | 276.96 |
12:18 ET | 800 | 277.25 |
12:20 ET | 200 | 277.35 |
12:23 ET | 700 | 277.04 |
12:27 ET | 400 | 277.21 |
12:32 ET | 100 | 277.38 |
12:36 ET | 100 | 277.33 |
12:38 ET | 200 | 277.31 |
12:39 ET | 400 | 276.945 |
12:41 ET | 700 | 276.34 |
12:48 ET | 180 | 276.02 |
12:50 ET | 100 | 276.26 |
12:52 ET | 100 | 276.27 |
12:54 ET | 300 | 276.26 |
12:56 ET | 400 | 276.175 |
01:01 ET | 500 | 275.985 |
01:03 ET | 100 | 276.01 |
01:06 ET | 300 | 276.69 |
01:10 ET | 100 | 276.82 |
01:12 ET | 200 | 276.895 |
01:15 ET | 100 | 277.3 |
01:17 ET | 4700 | 277.355 |
01:24 ET | 100 | 277.07 |
01:26 ET | 300 | 277.015 |
01:30 ET | 700 | 276.685 |
01:32 ET | 600 | 276.65 |
01:33 ET | 400 | 276.89 |
01:35 ET | 200 | 277.16 |
01:37 ET | 400 | 276.67 |
01:39 ET | 800 | 278.005 |
01:42 ET | 2000 | 277.47 |
01:44 ET | 1496 | 276.765 |
01:46 ET | 1300 | 276.83 |
01:50 ET | 219 | 276.2175 |
01:51 ET | 200 | 275.81 |
01:53 ET | 200 | 276 |
02:02 ET | 100 | 276.065 |
02:04 ET | 300 | 276.56 |
02:06 ET | 200 | 276.43 |
02:15 ET | 100 | 276.425 |
02:24 ET | 100 | 276.475 |
02:31 ET | 200 | 276.53 |
02:33 ET | 500 | 277.11 |
02:38 ET | 100 | 277.49 |
02:42 ET | 600 | 277.02 |
02:44 ET | 100 | 276.88 |
02:49 ET | 200 | 276.46 |
02:54 ET | 220 | 276.49 |
02:56 ET | 100 | 276.47 |
02:58 ET | 500 | 275.29 |
03:00 ET | 100 | 275.32 |
03:02 ET | 1100 | 275.7 |
03:03 ET | 500 | 275.575 |
03:09 ET | 2505 | 274.16 |
03:12 ET | 301 | 273.97 |
03:14 ET | 100 | 273.2 |
03:16 ET | 551 | 273.3971 |
03:18 ET | 400 | 273.78 |
03:21 ET | 100 | 273.655 |
03:23 ET | 600 | 273.25 |
03:25 ET | 100 | 273.2 |
03:30 ET | 100 | 273.48 |
03:32 ET | 200 | 273.94 |
03:36 ET | 200 | 273.925 |
03:38 ET | 600 | 273.345 |
03:39 ET | 200 | 273.53 |
03:43 ET | 700 | 273.535 |
03:45 ET | 600 | 272.435 |
03:48 ET | 300 | 272.305 |
03:50 ET | 200 | 272.1 |
03:52 ET | 200 | 271.785 |
03:54 ET | 500 | 272.21 |
03:56 ET | 1200 | 272.095 |
Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
---|---|---|---|
Madrigal Pharmaceuticals Inc | 6.0B | -11.8x | --- |
Viking Therapeutics Inc | 6.1B | -55.6x | --- |
Summit Therapeutics Inc | 5.7B | -45.8x | --- |
Cytokinetics Inc | 6.3B | -10.1x | --- |
Revolution Medicines Inc | 6.4B | -10.0x | --- |
Nuvalent Inc | 4.9B | -29.9x | --- |
Madrigal Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company. The Company is engaged in pursuing novel therapeutics for non-alcoholic steatohepatitis (NASH). The Company's product candidate, resmetirom, is a once-daily, oral, liver-directed thyroid hormone receptor-β (THR-β) agonist designed to target key underlying causes of NASH. NASH is a more advanced form of non-alcoholic fatty liver disease (NAFLD). The Company’s clinical development program includes MAESTRO-NASH, MAESTRO-NAFLD-1, and MAESTRO-NASH OUTCOMES.
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $6.0B |
---|---|
Revenue (TTM) | $0.00 |
Shares Outstanding | 21.3M |
Dividend Yield | 0.00% |
Annual Dividend Rate | --- |
Ex-Dividend Date | 01-01-01 |
Pay Date | 01-01-01 |
Beta | -0.43 |
EPS | $-23.08 |
Book Value | $20.39 |
P/E Ratio | -11.8x |
Price/Sales (TTM) | --- |
Price/Cash Flow (TTM) | --- |
Operating Margin | --- |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.